Relmada Therapeutics, Inc. RLMD Net realized gains (losses)
Net realized gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s net realized gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s net realized gains (losses)?
- Relmada Therapeutics, Inc. (RLMD) reported net realized gains (losses) of -$9.87K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s net realized gains (losses) changed year-over-year?
- Relmada Therapeutics, Inc.'s net realized gains (losses) decreased by 115.7% year-over-year, from $62.95K to -$9.87K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s net realized gains (losses)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s net realized gains (losses) has grown at a -40.6% compound annual growth rate (CAGR), from -$636.01K to -$79.21K.
- What does net realized gains (losses) mean?
- Captures the net profit or loss recognized upon the sale or maturity of investment securities. It indicates the effectiveness of the company's treasury management in liquidating assets to fund operational requirements.